Selected research
Industry Research
Eosinophilic Granulomatosis Industry Research Report 2026
Market perspective
The global Eosinophilic Granulomatosis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Eosinophilic Granulomatosis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Eosinophilic Granulomatosis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Eosinophilic Granulomatosis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Eosinophilic Granulomatosis include Sanofi, Novartis International, GlaxoSmithKline, Baxter, Amgen, AstraZeneca, Pharmaceuticals Holdings, Genentech(Roche) and DSM, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Eosinophilic Granulomatosis market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Eosinophilic Granulomatosis Market by Company
Sanofi
Novartis International
GlaxoSmithKline
Baxter
Amgen
AstraZeneca
Pharmaceuticals Holdings
Genentech(Roche)
DSM
Cephalon(Teva)
Eosinophilic Granulomatosis Segment by Type
Oral
Intravenous
Others
Eosinophilic Granulomatosis Segment by Application
Hospital Pharmacies
Drug Stores
Others
Eosinophilic Granulomatosis Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eosinophilic Granulomatosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Eosinophilic Granulomatosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eosinophilic Granulomatosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Eosinophilic Granulomatosis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Eosinophilic Granulomatosis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Eosinophilic Granulomatosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Intravenous
- Others
Applications
- Hospital Pharmacies
- Drug Stores
- Others
Companies covered
- Sanofi
- Novartis International
- GlaxoSmithKline
- Baxter
- Amgen
- AstraZeneca
- Pharmaceuticals Holdings
- Genentech(Roche)
- DSM
- Cephalon(Teva)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Eosinophilic Granulomatosis Market Size (2021-2032)
- 2.2.2 Global Eosinophilic Granulomatosis Sales (2021-2032)
- 2.2.3 Global Eosinophilic Granulomatosis Market Average Price (2021-2032)
- 2.3 Eosinophilic Granulomatosis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Intravenous
- 2.3.4 Others
- 2.4 Eosinophilic Granulomatosis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Drug Stores
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Eosinophilic Granulomatosis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Eosinophilic Granulomatosis Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Eosinophilic Granulomatosis Revenue of Manufacturers (2021-2026)
- 3.4 Global Eosinophilic Granulomatosis Average Price by Manufacturers (2021-2026)
- 3.5 Global Eosinophilic Granulomatosis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Eosinophilic Granulomatosis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Eosinophilic Granulomatosis, Product Type & Application
- 3.8 Global Manufacturers of Eosinophilic Granulomatosis, Established Date
- 3.9 Global Eosinophilic Granulomatosis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Eosinophilic Granulomatosis Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Novartis International
- 4.2.1 Novartis International Company Information
- 4.2.2 Novartis International Business Overview
- 4.2.3 Novartis International Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis International Eosinophilic Granulomatosis Product Portfolio
- 4.2.5 Novartis International Recent Developments
- 4.3 GlaxoSmithKline
- 4.3.1 GlaxoSmithKline Company Information
- 4.3.2 GlaxoSmithKline Business Overview
- 4.3.3 GlaxoSmithKline Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline Eosinophilic Granulomatosis Product Portfolio
- 4.3.5 GlaxoSmithKline Recent Developments
- 4.4 Baxter
- 4.4.1 Baxter Company Information
- 4.4.2 Baxter Business Overview
- 4.4.3 Baxter Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter Eosinophilic Granulomatosis Product Portfolio
- 4.4.5 Baxter Recent Developments
- 4.5 Amgen
- 4.5.1 Amgen Company Information
- 4.5.2 Amgen Business Overview
- 4.5.3 Amgen Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Amgen Eosinophilic Granulomatosis Product Portfolio
- 4.5.5 Amgen Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Eosinophilic Granulomatosis Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Pharmaceuticals Holdings
- 4.7.1 Pharmaceuticals Holdings Company Information
- 4.7.2 Pharmaceuticals Holdings Business Overview
- 4.7.3 Pharmaceuticals Holdings Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pharmaceuticals Holdings Eosinophilic Granulomatosis Product Portfolio
- 4.7.5 Pharmaceuticals Holdings Recent Developments
- 4.8 Genentech(Roche)
- 4.8.1 Genentech(Roche) Company Information
- 4.8.2 Genentech(Roche) Business Overview
- 4.8.3 Genentech(Roche) Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Genentech(Roche) Eosinophilic Granulomatosis Product Portfolio
- 4.8.5 Genentech(Roche) Recent Developments
- 4.9 DSM
- 4.9.1 DSM Company Information
- 4.9.2 DSM Business Overview
- 4.9.3 DSM Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 DSM Eosinophilic Granulomatosis Product Portfolio
- 4.9.5 DSM Recent Developments
- 4.10 Cephalon(Teva)
- 4.10.1 Cephalon(Teva) Company Information
- 4.10.2 Cephalon(Teva) Business Overview
- 4.10.3 Cephalon(Teva) Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cephalon(Teva) Eosinophilic Granulomatosis Product Portfolio
- 4.10.5 Cephalon(Teva) Recent Developments
5 Global Eosinophilic Granulomatosis Market Scenario by Region
- 5.1 Global Eosinophilic Granulomatosis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Eosinophilic Granulomatosis Sales by Region: 2021-2032
- 5.2.1 Global Eosinophilic Granulomatosis Sales by Region: 2021-2026
- 5.2.2 Global Eosinophilic Granulomatosis Sales by Region: 2027-2032
- 5.3 Global Eosinophilic Granulomatosis Revenue by Region: 2021-2032
- 5.3.1 Global Eosinophilic Granulomatosis Revenue by Region: 2021-2026
- 5.3.2 Global Eosinophilic Granulomatosis Revenue by Region: 2027-2032
- 5.4 North America Eosinophilic Granulomatosis Market Facts & Figures by Country
- 5.4.1 North America Eosinophilic Granulomatosis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Eosinophilic Granulomatosis Sales by Country (2021-2032)
- 5.4.3 North America Eosinophilic Granulomatosis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Eosinophilic Granulomatosis Market Facts & Figures by Country
- 5.5.1 Europe Eosinophilic Granulomatosis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Eosinophilic Granulomatosis Sales by Country (2021-2032)
- 5.5.3 Europe Eosinophilic Granulomatosis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Eosinophilic Granulomatosis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Eosinophilic Granulomatosis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Eosinophilic Granulomatosis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Eosinophilic Granulomatosis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Eosinophilic Granulomatosis Market Facts & Figures by Country
- 5.7.1 South America Eosinophilic Granulomatosis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Eosinophilic Granulomatosis Sales by Country (2021-2032)
- 5.7.3 South America Eosinophilic Granulomatosis Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Eosinophilic Granulomatosis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Eosinophilic Granulomatosis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Eosinophilic Granulomatosis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Eosinophilic Granulomatosis Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Eosinophilic Granulomatosis Sales by Type (2021-2032)
- 6.1.1 Global Eosinophilic Granulomatosis Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Eosinophilic Granulomatosis Sales Market Share by Type (2021-2032)
- 6.2 Global Eosinophilic Granulomatosis Revenue by Type (2021-2032)
- 6.2.1 Global Eosinophilic Granulomatosis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Eosinophilic Granulomatosis Revenue Market Share by Type (2021-2032)
- 6.3 Global Eosinophilic Granulomatosis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Eosinophilic Granulomatosis Sales by Application (2021-2032)
- 7.1.1 Global Eosinophilic Granulomatosis Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Eosinophilic Granulomatosis Sales Market Share by Application (2021-2032)
- 7.2 Global Eosinophilic Granulomatosis Revenue by Application (2021-2032)
- 7.2.1 Global Eosinophilic Granulomatosis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Eosinophilic Granulomatosis Revenue Market Share by Application (2021-2032)
- 7.3 Global Eosinophilic Granulomatosis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Eosinophilic Granulomatosis Value Chain Analysis
- 8.1.1 Eosinophilic Granulomatosis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Eosinophilic Granulomatosis Production Mode & Process
- 8.2 Eosinophilic Granulomatosis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Eosinophilic Granulomatosis Distributors
- 8.2.3 Eosinophilic Granulomatosis Customers
9 Global Eosinophilic Granulomatosis Analyzing Market Dynamics
- 9.1 Eosinophilic Granulomatosis Industry Trends
- 9.2 Eosinophilic Granulomatosis Industry Drivers
- 9.3 Eosinophilic Granulomatosis Industry Opportunities and Challenges
- 9.4 Eosinophilic Granulomatosis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst